MDACC Study No:2011-0579 ( NCT No: NCT01619774)
Title:An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients with Metastatic Melanoma which is Refractory or Resistant to BRAF Inhibitor
Principal Investigator:Michael Davies
Treatment Agent:GSK1120212 ; GSK2118436
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn if the combination of 2
drugs dabrafenib and trametinib can help to control melanoma that has or has
not spread to the brain. The safety of this drug combination will also be

Dabrafenib is designed to block the mutated BRAF protein. This mutation is
only found in moles of the skin and in melanoma cells. By blocking the protein,
the drug may slow the growth of or kill cancer cells that have the protein.

Trametinib is designed to block certain proteins that cause cancer cells to
grow and multiply. This may cause the cancer cells to die.
Hide details for General InformationGeneral Information

Disease Group:Melanoma
Phase of Study:Phase II
Treatment Agents:GSK1120212
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:Cancer Prevention Research Institute of Texas (CPRiT)
Glaxo Smith Kline
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Michael Davies
Dept:Melanoma Medical Oncology
For Clinical Trial Enrollment:713-792-2921
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults